Coltene Holding Ag · SIX:CLTN
Coltene — H1 2021 Earnings Presentation
28 slides from Coltene's earnings presentation, Aug 6, 2021
Slide 1: Rebounding Growth
Rebounding Growth Half-Year Results 2021 COLTENE Group – Media and Financial Analysts Conference Call Martin Schaufelberger, CEO Gerhard Mahrle, CFO 6 August 2021
Slide 2: Safe Harbor Statement
Safe Harbor Statement This written statement and oral statements or other statements made, or to be made, by us contain forward-looking statements that do not relate solely to historical or current facts. These forward-looking statements are based on the current plans and expectations of our managem
Slide 3: Agenda
Agenda Media and financial analysts conference call H1 2021 Highlights H1 2021 Martin Schaufelberger, CEO Financials H1 2021 Gerhard Mahrle, CFO Outlook Martin Schaufelberger, CEO Q&A All Interim Reporting 2021 3
Slide 4: Highlights H1 2021
Highlights H1 2021 Martin Schaufelberger, CEO
Slide 5: H1 2021 Highlights
H1 2021 Highlights Recovery in demand and cost control lead to record high semester results Financials • Net sales CHF 143.5 mn; +43.0% adjusted for divestments and in local currencies compared to H1 2020; +38.1% in reporting currency Swiss francs • Strong Swiss franc appreciated against the USD a
Slide 6: Product Group Structure
Product Group Structure Strong combined portfolio Infection Control Dental Preservation Efficient Treatment „The infection „Sustainable preservation „Smart & efficient control specialist“ from root to crown“ utilities dentists rely on“ Instrument reprocessing Materials for restoration Impression mat
Slide 7: Net Sales by Product Groups
Net Sales by Product Groups Products in the area Infection Control still in great demand in H1 2021 - rebound of other areas Net sales H1 2021 by product groups Net sales H1 2020 & 2021 by product groups (in CHF 1’000) (shares) H1 2020 H1 2021 28.6% 60’000 52’150 50’308 36.3% 50’000 40’129 41’011 37
Slide 8: Net Sales by Region
Net Sales by Region North America remains strongest market Net sales H1 2020 & 2021 by regions (in CHF 1’000) Net sales H1 2021 by regions (shares) H1 2020 H1 2021 80’000 72’170 4.3% 70’000 10.4% 60’000 49’730 50’226 50’000 50.3% 40’000 34’773 35.0% 30’000 20’000 14’055 14’933 10’000 5’330 6’139 0 N
Slide 9: COVID Impact and Rebound in Context
COVID Impact and Rebound in Context Strategic acquisition – focus Infection Control – COVID impact – fast intervention – rebound – ready for organic growth 2018 2019 2020 2021 2022 integration acquisition of awareness of Infection Control SciCan & Micro-Mega COVID19 rebound anorganic growth COVID im
Slide 10: Financials H1 2021
Financials H1 2021 Gerhard Mahrle, CFO
Slide 11: Financial Summary H1 2021
Financial Summary H1 2021 Strong start into 2021: record high sales and results Sales • H1 2021 sales at CHF 143.5 mn (H1 2020: CHF 103.9 mn; +38.1% above PY) • Net sales adjusted by divestment and in local currency up by 43.0% • Strong Swiss franc reduced sales by CHF 2.7 mn • Strong demand for I
Slide 12: Income Statement
Income Statement Rise of EBIT margin from 2.5% to 18.1% in CHF mn H1 2020 % H1 2021 % % YoY • Net sales increase mainly driven by recovery and restocking effects (negative Net sales 103.9 100.0 143.5 100.0 38.1% currency impact on sales CHF 2.7 mn) Material expenses -35.1 -33.8 -46.5 -32.4 32.6% • G
Slide 13: EBIT Development H1 2020 – H1 2021
EBIT Development H1 2020 – H1 2021 Record high EBIT driven by sales recovery in H1 2021 EBIT Bridge YTD H1 2020 to H1 2021 - in CHF mn 35 30 -4.7 25 +0.1 -0.1 Negative currency impact on Gross Profit of CHF 1.9mn 20 15 +30.0 26.0 10 5 2.6 -1.9 0 EBIT YTD FX GP Gross PEEX OPEX D&A EBIT YTD OPEX remai
Slide 14: Net Profit
Net Profit Net profit boosted by excellent operational results – normalized tax rate Overall decrease in financial expenses: Tax rate decrease: Net profit in CHF mn: FX losses in various countries partially Effective tax rate decreased from 80.9% to compensated by FX gains in Canada 27.4% (p
Slide 15: Balance Sheet
Balance Sheet Ensuring adequate liquidity and a healthy balance sheet in CHF million 31.12.20 30.06.21 % YoY • Decrease in cash due to the payment of Cash & cash equivalents 38.5 28.2 -26.6% CHF 17.9 mn dividend in April 2021 Receivables 45.1 45.2 0.3% • General increase of working capital due to In
Slide 16: Equity
Equity Increase of equity ratio despite balance sheet growth Net Debt 30.4 In CHF million 21.9 Net debt: CHF 30.4 mn (Dec 2020: CHF 21.9 mn) Total assets slightly increased driven by business recovery Equity ratio: 49.5% (Dec 2020: 48.1%) 31.12.2020 30.06.2021 Balance Sheet 193.3 187.6 95.7 55
Slide 17: Cash Flow Statement
Cash Flow Statement Pleasant operating cash flow and record high free cash flow in CHF million H1 2020 H1 2021 % YoY • Higher operating cash flow due to Net profit 0.3 18.2 6 172.1% rebounding business despite increasing Depreciation and amortization 3.0 3.1 working capital and higher taxes paid Oth
Slide 18: Outlook
Outlook Martin Schaufelberger, CEO
Slide 19: COLTENE Recovery and Outlook after COVID
COLTENE Recovery and Outlook after COVID Strategic acquisition – focus infection control – COVID impact – fast intervention – rebound – ready for organic growth Sales development HY1'19 - HY1’21 Sales development FY1'19 - FY'21 (projected) Net sales in CHFm (@constant FX 2019) Net sales in CHFm (@co
Slide 20: What can we expect in 2021?
What can we expect in 2021? Impact by and recovery from COVID-19 Expected • Sales between CHF 270.0 mn and 280.0 mn for FY 2021 Results • Raw material supply is important to assure production volume • Cost increase in T&E, marketing and personnel as pandemic ends • For FY 2021 an EBIT margin of ab
Slide 21: Q&A
Q&A Rebounding Growth ” COLTENE
Slide 22: Annex
Annex “” COLTENE
Slide 23: Dental Industry
Dental Industry Mega trends COVID-19 pandemic Globalization and e-commerce Increasing requirements in distribution regarding quality management and regulatory affairs (MDR) Negative trend in volume due to Digitalization in better oral health in Consolidation • the dental processes developed countrie
Slide 24: Organization
Organization Management Board of Directors Group Management Matthew Robin Christophe Loretan, VP Sales / MarCom EMEA / ROW Martin Schaufelberger, CEO Allison Zwingenberger Astrid Waser Stefan Helsing, COO Martin Schlüter, VP R&D / Innovation Jürgen Rauch Roland Weiger Werner Barth, VP Product Gerhar
Slide 25: COLTENE Overview
COLTENE Overview Top quality dental supplier • COLTENE develops, manufactures and markets premium dental materials and small Altstätten (Switzerland) Dental Preservation Efficient Treatment equipment for dental practices • 5 specialized manufacturing sites Toronto (Canada) Infection Control • MedTec
Slide 26: 5-Year Financial Overview
5-Year Financial Overview Key Figures in H1 (2017: IFRS / since 2018 Swiss GAAP FER) in CHF million Net sales in CHF million EBIT EBIT margin in % 28 18.1% 20% 140 24 120 20 15% 12.3% 12.0% 100 16 9.4% 10% 12 80 8 5% 60 2.5% 4 78.0 85.6 135.4 103.9 143.5 9.6 10.2 12.8 26.0 40 2… 0 0% H1 2017 H1 2018
Slide 27: Share Performance
Share Performance Volatile financial market environment Share price Earnings per share/dividend COLTENE SPI Earnings per Share Dividend 140 5 4.52 130 4.10 120 4 3.61 3.35 3.0 3.0 3.0 110 100 3 2.7 90 2 80 1.5 1.38 70 1 60 50 0 40 2016 2017 2018 2019 2020 Interim Reporting 2021 27
Slide 28: Visit us on our website: www.coltene.com
COLTENE Holding AG Visit us on our website: Martin Schaufelberger, CEO Gerhard Mahrle, CFO www.coltene.com Feldwiesenstrasse 20 9450 Altstätten +41 71 757 53 80 investor@coltene.com